RXSTRxSight, Inc.
Ophthalmic Goods
- Revenue
- $134M
- 3.9% YoY
- Operating margin
- -35.8%
- 36% YoY
- EBITDA
- −$45M
- 35% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$13M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired24% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $23M | $49M | $89M | $140M | $134M | 3.9% |
| Operating income | −$53M | −$63M | −$50M | −$37M | −$48M | 31% |
| Net income | −$49M | −$67 | −$49 | −$28 | −$39 | 41% |
| Operating cash flow | −$45M | −$59M | −$42M | −$17M | −$16M | 8.5% |
| Capex | $2M | $2M | $5M | $5M | $4M | 30% |
| Stock-based comp | $8M | $11M | $16M | $25M | $32M | 28% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | −$2M | 93 | 76 |
| FY2024 | $7M | $5M | 306 | 76 |
| FY2023 | $3M | $12M | 358 | 72 |
| FY2022 | $1M | $1M | 113 | 77 |